News & Updates

Back to All News

Bryn Mawr Hospital first in region to offer cutting-edge Lithoplasty® Technology for peripheral artery disease

Bryn Mawr Hospital August 21, 2017 News Releases

Novel technology uses sonic pressure waves to treat leg artery blockages

Bryn Mawr Hospital, part of Main Line Health’s Lankenau Heart Institute, has announced the availability of a novel treatment for those suffering from peripheral artery disease (PAD). Bryn Mawr is the first in the region to offer Shockwave Medical’s Lithoplasty® system, an innovative therapy designed to treat calcified leg artery blockages with lithotripsy. This sonic pressure wave treatment has been derived from a similar therapy used to treat patients with kidney stones.

PAD blocks blood flow to the legs and feet, causing significant pain and limited mobility, potentially leading to surgery or even amputation in severe cases. Caused by the buildup of plaque and calcium within the walls of arteries, PAD occurs primarily in the legs, but can be found in vessels throughout the body. Balloon angioplasty, which involves inflating a balloon within the artery at the area of narrowing and expanding the artery to alleviate the blockage, is commonly used to treat PAD. Many patients do not respond well to angioplasty alone, with failure rates as high as 50 percent often due to hardened calcium within the wall of the artery.

“This is yet another example of the Lankenau Heart Institute’s commitment to providing cutting-edge treatment options for patients with heart and vascular conditions,” said Sarang Mangalmurti, MD, an interventional cardiologist at Bryn Mawr Hospital. “We’re thrilled to be the first in the region to offer this technology, which gives us the ability to more effectively treat hardened calcium with potentially less risk of damage or injury to the vessel.”

Shockwave Medical’s Lithoplasty system integrates angioplasty balloon catheter devices with the calcium-disrupting power of sonic pressure waves, known as lithotripsy. Each Lithoplasty catheter incorporates multiple lithotripsy emitters activated with the touch of a button after the balloon is inflated. Once activated, these emitters produce therapeutic sonic pressure waves that are inherently tissue-selective, passing through the balloon and soft vascular tissue, without damage and preferentially disrupting the calcified plaque inside the vessel wall by creating a series of micro-fractures. When the calcium has been modified, the vessel can be dilated using low pressures, thereby enabling even historically challenging PAD patients to be treated effectively with minimal injury to the vessel.

The technology is now commercially available in both the United States and Europe for the treatment of calcified plaque in peripheral arteries. On behalf of Lankenau Heart Institute, Bryn Mawr Hospital is serving as a clinical test site for Lithoplasty and will continue to participate in trials evaluating best practice usage and the effectiveness of this technology. William Gray, MD, system chief of the division of cardiovascular disease at Main Line Health and president of the Lankenau Heart Institute, is leading this important trial as its national principle investigator.

The Shockwave Medical Lithoplasty system is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. Not for use in the coronary or cerebral vasculature.

To view an animation of the Lithoplasty system, visit shockwavemedical.com/us

About Main Line Health

Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.

At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.

Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.

About Bryn Mawr Hospital

Bryn Mawr Hospital, a member of Main Line Health, is a 287-bed, not-for-profit acute-care teaching hospital dedicated to helping the community stay well ahead on the path to lifelong health. Bryn Mawr Hospital has been named as one of the top six hospitals in the Philadelphia region and top 12 in the state of Pennsylvania by U.S. News & World Report’s Best Hospitals 2017–18, and is ranked as high-performing in the specialties of gastroenterology & GI surgery, geriatrics and orthopedics. U.S. News & World Report also ranked Bryn Mawr Hospital as high performing in the following procedures/conditions: COPD, colon cancer surgery, heart failure, hip replacement and knee replacement. Bryn Mawr Hospital has earned Magnet® designation for the third time for its superior nursing staff. Bryn Mawr Hospital’s Neuro-Cardiac Intensive Care Unit (NCICU) has also received the 2015–18 American Association of Critical-Care Nurses (AACN) Silver-level Beacon Award for Excellence for the second time. The National Institutes of Health Commission on Cancer has accredited our Cancer Center and our Comprehensive Breast Center has been accredited by The Joint Commission and the National Accreditation Program for Breast Centers. Bryn Mawr Hospital’s Bariatric Program has earned the MBSAQIP Accredited Comprehensive Center designation from the American Society of Metabolic and Bariatric Surgery. The hospital offers a full range of services, including cancer care, orthopedic care, cardiovascular care, behavioral health, maternity care, bariatric surgery, neurovascular and a level III neonatal intensive care unit, all aided by a dedicated team of health care professionals and innovative technologies. Through Bryn Mawr Hospital’s collaboration with the Jefferson Hospital for Neuroscience, the university-affiliated Neurovascular Center offers rapid access to advanced diagnostics and treatment options for stroke care. Bryn Mawr Hospital has also collaborated with Nemours/Alfred I. duPont Hospital for Children to include round-the-clock pediatric care for the pediatric unit and in the pediatric emergency department with additional board-certified, fellowship trained pediatric emergency medicine physicians.

Contact

Whitney Ehret
Communications Specialist
Office: 484.580.1059
Cell: 215.264.0343
ehretw@mlhs.org